Cargando…

Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data

AIMS: Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in the prevention of thromboembolism in patients with atrial fibrillation. However, their real-world clinical outcomes appear to be contradictory, with some studies reporting fewer and others reporting higher c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moret, Carla, Acosta-Isaac, René, Mojal, Sergi, Corrochano, Mariana, Jiménez, Blanca, Plaza, Melania, Souto, Juan Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955586/ https://www.ncbi.nlm.nih.gov/pubmed/36827286 http://dx.doi.org/10.1371/journal.pone.0279297

Ejemplares similares

Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants
por: Corrochano, Mariana, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
por: Hardy, Michael, et al.
Publicado: (2022)

Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era
por: Sehrawat, Ojasav, et al.
Publicado: (2023)

Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency
por: Hahn, Kai, et al.
Publicado: (2023)

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
por: Dunois, Claire
Publicado: (2021)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
por: Schwarb, Heike, et al.
Publicado: (2016)

Spontaneous rectal sheath bleed while on DOAC anticoagulation
por: de Courcy, Louis, et al.
Publicado: (2023)

Which Renal Function Equation Should Be Used for Prescribing DOACs in Patients With Atrial Fibrillation?
por: Wang, Yilong, et al.
Publicado: (2022)

Optimization of DOAC management services in a centralized anticoagulation clinic
por: Sylvester, Katelyn W., et al.
Publicado: (2022)

Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry
por: Dong, Zhimin, et al.
Publicado: (2022)

Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study
por: Esposti, Luca D, et al.
Publicado: (2019)

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
por: Cao, Yalin, et al.
Publicado: (2022)

Anticoagulation in atrial fibrillation
por: Steinberg, Benjamin A, et al.
Publicado: (2014)

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
por: Burnett, Allison E., et al.
Publicado: (2016)

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review
por: Sunkara, Tagore, et al.
Publicado: (2016)

Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
por: Doucette, Kimberley, et al.
Publicado: (2020)

Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine
por: Harenberg, Job, et al.
Publicado: (2021)

Direct Oral Anticoagulants (DOAC): Are We Ready for a Pharmacogenetic Approach?
por: Palmirotta, Raffaele
Publicado: (2021)

DOACs in the Anticoagulation of Mechanical Valves: A Systematic Review and Future Perspectives
por: Langenaeken, Tom, et al.
Publicado: (2023)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
por: Baker, Steven Andrew, et al.
Publicado: (2021)

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC
por: Blin, Patrick, et al.
Publicado: (2015)

The Distribution of the Genotypes of ABCB1 and CES1 Polymorphisms in Kazakhstani Patients with Atrial Fibrillation Treated with DOAC
por: Abdrakhmanov, Ayan, et al.
Publicado: (2023)

Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2022)

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
por: Noviyani, Rini, et al.
Publicado: (2022)

Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19
por: Corrochano, Mariana, et al.
Publicado: (2021)

The effectiveness of atrial fibrillation special clinic on oral anticoagulant use for high risk atrial fibrillation patients managed in the community
por: Lau, Ka Man, et al.
Publicado: (2023)

Drug Use Evaluation of Direct Oral Anticoagulants (DOACs) in Patients With Advanced Cirrhosis
por: Jarboe, Lindsey, et al.
Publicado: (2022)

Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
por: Zeng, Shan, et al.
Publicado: (2022)

Satisfaction with oral anticoagulants in patients with atrial fibrillation
por: Suárez Fernández, Carmen, et al.
Publicado: (2018)

Anticoagulation After Ischemic Stroke or Transient Ischemic Attack (TIA) in the Time of Direct Oral Anticoagulation (DOAC) and Thrombectomy
por: Martin Diaz, Claudia, et al.
Publicado: (2021)

Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis
por: Emanuel, Subo, et al.
Publicado: (2023)

Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
por: Bisson, Arnaud, et al.
Publicado: (2017)

Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update
por: Shah, Shagun B, et al.
Publicado: (2019)

Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase(®)
por: Sessa, Maurizio, et al.
Publicado: (2019)

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
por: Ferri, Nicola, et al.
Publicado: (2022)

Novel Ex Vivo DOAC Removal Methods Reduce Interference in Lupus Anticoagulant Testing
por: Savola, Paula, et al.
Publicado: (2022)

Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples
por: Linskens, Eleni A., et al.
Publicado: (2022)

Patterns of Anticoagulation Use in Patients With Cancer With Atrial Fibrillation and/or Atrial Flutter
por: Fradley, Michael G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ui244ognj0um6b5r3dk4q10t72